336 related articles for article (PubMed ID: 26938947)
61. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
62. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.
Rancan C; Schirrmann L; Hüls C; Zeidler R; Moosmann A
PLoS Pathog; 2015 Jun; 11(6):e1004906. PubMed ID: 26067064
[TBL] [Abstract][Full Text] [Related]
63. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
[TBL] [Abstract][Full Text] [Related]
64. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
Kim WS; Oki Y; Kim SJ; Yoon SE; Ardeshna KM; Lin Y; Ruan J; Porcu P; Brammer JE; Jacobsen ED; Yoon DH; Suh C; Suarez F; Radford J; Budde LE; Kim JS; Bachy E; Lee HJ; Bollard CM; Jaccard A; Kang HJ; Inman S; Murray M; Combs KE; Lee DY; Advani R; Gunter KC; Rooney CM; Heslop HE
Ann Hematol; 2021 Oct; 100(10):2529-2539. PubMed ID: 34304287
[TBL] [Abstract][Full Text] [Related]
65. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients.
Petrova M; Muhtarova M; Nikolova M; Magaev S; Taskov H; Nikolovska D; Krastev Z
World J Gastroenterol; 2006 Sep; 12(35):5711-6. PubMed ID: 17007027
[TBL] [Abstract][Full Text] [Related]
66. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
Turcanová V; Höllsberg P
J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
[TBL] [Abstract][Full Text] [Related]
67. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
68. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
[TBL] [Abstract][Full Text] [Related]
69. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
Ngo MC; Ando J; Leen AM; Ennamuri S; Lapteva N; Vera JF; Min-Venditti A; Mims MP; Heslop HE; Bollard CM; Gottschalk S; Rooney CM
J Immunother; 2014 May; 37(4):193-203. PubMed ID: 24714353
[TBL] [Abstract][Full Text] [Related]
70. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
71. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
[TBL] [Abstract][Full Text] [Related]
72. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.
Cho SG; Kim N; Sohn HJ; Lee SK; Oh ST; Lee HJ; Cho HI; Yim HW; Jung SE; Park G; Oh JH; Choi BO; Kim SW; Kim SW; Chung NG; Lee JW; Hong YS; Kim TG
Mol Ther; 2015 Aug; 23(8):1401-1409. PubMed ID: 26017177
[TBL] [Abstract][Full Text] [Related]
73. Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.
Landmeier S; Altvater B; Pscherer S; Juergens H; Varnholt L; Hansmeier A; Bollard CM; Moosmann A; Bisping G; Rossig C
J Immunother; 2009 Apr; 32(3):310-21. PubMed ID: 19242369
[TBL] [Abstract][Full Text] [Related]
74. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
75. T lymphocytes targeting native receptors.
Rooney CM; Leen AM; Vera JF; Heslop HE
Immunol Rev; 2014 Jan; 257(1):39-55. PubMed ID: 24329788
[TBL] [Abstract][Full Text] [Related]
76. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.
Sun L; Hao Y; Wang Z; Zeng Y
Viruses; 2018 Mar; 10(4):. PubMed ID: 29570629
[TBL] [Abstract][Full Text] [Related]
77. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy.
Dudaniec K; Westendorf K; Nössner E; Uckert W
Hum Gene Ther; 2021 Sep; 32(17-18):919-935. PubMed ID: 33798008
[TBL] [Abstract][Full Text] [Related]
78. EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias.
Xiao W; Li L; Zhou R; Xiao R; Wang Y; Ji X; Wu M; Wang L; Huang W; Zheng X; Tan X; Chen L; Xiong T; Xiong J; Jin Y; Tan J; He Y
Cell Mol Immunol; 2009 Oct; 6(5):367-79. PubMed ID: 19887050
[TBL] [Abstract][Full Text] [Related]
79. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.
Angelini DF; Serafini B; Piras E; Severa M; Coccia EM; Rosicarelli B; Ruggieri S; Gasperini C; Buttari F; Centonze D; Mechelli R; Salvetti M; Borsellino G; Aloisi F; Battistini L
PLoS Pathog; 2013; 9(4):e1003220. PubMed ID: 23592979
[TBL] [Abstract][Full Text] [Related]
80. Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders.
McLaughlin LP; Bollard CM; Keller MD
Front Immunol; 2018; 9():556. PubMed ID: 29616044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
